Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1478Leukemia, Myeloid, Acute 1239Leukemia, Myelogenous, Chronic, BCR-ABL Positive 863Leukemia 745Precursor Cell Lymphoblastic Leukemia-Lymphoma 704Myeloproliferative Disorders 631Leukemia, Myelomonocytic, Chronic 455Lymphoma, Non-Hodgkin 447Primary Myelofibrosis 430Multiple Myeloma 423Leukemia, Lymphocytic, Chronic, B-Cell 408Hodgkin Disease 384Lymphoma 343Leukemia, Myeloid, Chronic-Phase 335Blast Crisis 282Polycythemia Vera 267Leukemia, Myeloid, Accelerated Phase 263Lymphoma, Follicular 254Lymphoma, Mantle-Cell 253Burkitt Lymphoma 246Lymphoma, Large B-Cell, Diffuse 244Lymphoma, B-Cell, Marginal Zone 225Congenital Abnormalities 215Lymphoma, Large-Cell, Immunoblastic 201Myelodysplastic-Myeloproliferative Diseases 199Thrombocythemia, Essential 197Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 196Anemia, Refractory, with Excess of Blasts 194Hematologic Neoplasms 193Neoplasms, Plasma Cell 184

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Translocation, Genetic × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡